HDAC-IN-47
Based on 1 publication(s) in Google Scholar
HDAC-IN-47 is an orally active inhibitor of histone deacetylase (HDAC), with IC50s of 19.75 nM (HDAC1), 5.63 nM (HDAC2), 40.27 nM (HDAC3), 57.8 nM (HDAC2), 302.73 nM (HDAC8), respectively. HDAC-IN-47 inhibits autophagy and induces apoptosis via the Bax/Bcl-2 and caspase-3 pathways. HDAC-IN-47 arrests cell cycle at G2/M phase, and shows anti-tumor efficacy in vivo.
For research use only. We do not sell to patients.
- CAS No.: 3033608-94-2
- Formula: C17H20BrN3O4
- Molecular Weight:410.26
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) HDAC-IN-47
More
Biological Activity
|
HDAC1 19.75 nM (IC50) |
HDAC6 5.63 nM (IC50) |
HDAC3 40.27 nM (IC50) |
HDAC2 57.8 nM (IC50) |
HDAC8 302.73 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.24 μM
Compound: 21
|
Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis
Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis
|
[PMID: 36215854] |
| HepG2 | IC50 |
0.16 μM
Compound: 21
|
Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis
Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis
|
[PMID: 36215854] |
| HL-60 | IC50 |
0.22 μM
Compound: 21
|
Anticancer activity against human HL-60 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis
Anticancer activity against human HL-60 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis
|
[PMID: 36215854] |
| MDA-MB-238 | IC50 |
0.45 μM
Compound: 21
|
Anticancer activity against human MDA-MB-238 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis
Anticancer activity against human MDA-MB-238 cells assessed as cell growth inhibition measured after 72 hrs by CCK-8 staining based microplate reader analysis
|
[PMID: 36215854] |
HDAC-IN-47 (compound 21) shows antiproliferative activity and inhibits A549 cell growth with an IC50 value of 0.24 μM[1].
HDAC-IN-47 (0.5 and 1 μM; 72 h) exhibits profound G2/M arrest in A549 cells and induces cell apoptosis[1].
HDAC-IN-47 (0.1 and 0.5 μM; 24 h) increases the expression levels of Bax and Caspase3, decreases the level of Bcl-2, activates the intrinsic (mitochondrial) apoptotic pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HepG2, MDA-MB-238, HL-60 cells
-
Concentration:0.16-0.45 μM
-
Incubation Time:72 hours
-
Result:Inhibited cancer cells with IC50s of 0.16 μM (HepG2), 0.45 μM (MDA-MB-238), 0.22 μM (HL-60), respectively.
-
Cell Line:A549 cells
-
Concentration:0.5 and 1 μM
-
Incubation Time:24 hours
-
Result:Induced marked arrest of cells in the G2/M phase of 28.38% (0.5 μM) and 31.70% (1.0 μM).
-
Cell Line:A549 cells
-
Concentration:0.5 and 1 μM
-
Incubation Time:24 hours
-
Result:Resulted 21.09% (0.5 μM) and 30.58% (1 μM) apoptotic cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:A549 xenograft model in mouse (female, BALB/c nu/nu mice, 6-8 weeks old)[1]
-
Dosage:50 mg/kg; 100 mg/kg
-
Administration:Oral gavage; once daily; for 18 consecutive days
-
Result:Decreased the tumor volume and weight by 48% and 45%, respectively.
Chemical Information
-
CAS No. 3033608-94-2
-
Molecular Weight 410.26
-
Formula C17H20BrN3O4
-
SMILES
O=C(C1=NC=C(C2=CC=C(Br)C=C2)O1)NCCCCCCC(NO)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)